Viatris sues Novo Nordisk over Wegovy patent dispute

Key Facts

1Viatris has filed a lawsuit against Novo Nordisk regarding a patent dispute over a generic version of the weight-loss drug Wegovy.

Viatris has filed a lawsuit against Novo Nordisk regarding a patent dispute over a generic version of the weight-loss drug Wegovy. Investing.com reported that the legal action aims to invalidate or bypass existing patents held by Novo Nordisk, which currently prevent competitors from launching generic alternatives of semaglutide.

VTRS closed at $17.42 on September 24, 2026, having traded between a low of $17 and a high of $17.45 during that session. The challenge to these blockbuster drug patents represents a significant move for Viatris, although the resolution of such pharmaceutical litigation often takes several years to conclude.